

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1648
Bw

Applicant: AOYAGI, et al.

Examiner: Z. Lucas

Serial No.: 09/509,449

Group Art Unit: 1648

Filed: March 28, 2000

Docket: 594.352USWO

Confirmation 8016

Notice of Allow. n/a

Due Date:

n/a

Date:

Title: METHOD FOR MEASUREMENT OF HEPATITIS C VIRUS

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 10, 2004.

By:

Name: Peggy Kerkhove

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

23552

PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Supplemental Information Disclosure Statement, Form 1449, 9 Reference(s), Copy of European Search Report
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300

By:

Name: Douglas P. Mueller

Reg. No.: 30,300

DPM/pjk

S/N 09/509,449

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: AOYAGI, et al. Examiner: Z. Lucas
Serial No.: 09/509,449 Group Art Unit: 1648
Filed: March 28, 2000 Docket No.: 594.352USWO
Title: METHOD FOR MEASUREMENT OF HEPATITIS C VIRUS

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450 on December 10, 2004.

By:

Name: Peggy Kerkhove

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. At least some of the references were recently cited in a European Search Report mailed November 11, 2004.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. No fee is due as this statement is submitted as certified below under 37 C.F.R. §1.97(e)(1) or (2) by the undersigned.

Certification Under 37 C.F.R. §1.97(e)(1)

In accordance with 37 C.F.R. §1.97(c) or §1.97(d), the undersigned hereby certifies that each item of information listed on the enclosed Form 1449 was first cited in a communication

from a foreign patent office in a counterpart foreign application within three months of filing this statement.

Certification Under 37 C.F.R. § 1.704(d)

In accordance with 37 C.F.R. § 1.704(d), the undersigned hereby certifies that each item listed on the enclosed Form 1449 was cited in a communication from a foreign patent office in a counterpart application, and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement. Accordingly, no patent term adjustment is due for the filing of this Information Disclosure Statement.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
(612)332.5300


Dated: December 10, 2004

By: 
Douglas P. Mueller
Reg. No. 30,300

DPM/pjk



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 594.352USWO	Application Number: 09/509,449
	Applicant: AOYAGI, et al.	
	Filing Date: March 28, 2000	Group Art Unit: 1648



U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,645,983	July, 1997	Liao, et al.			
	5,330,893	July, 1994	Gilbert, et al.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 173 295	March, 1986	EPO				
	0 351 248	January, 1990	EPO				
	93/21346	October, 1993	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Kashiwakuma, et al., "Detection of hepatitis C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay (FEIA), Journal of Immunological Methods 190 (1996) 79-89
		Atherton, et al., "A sensitive Screening Test for the Simultaneous Detection of Hepatitis B Surface Antigen and Antibody", Journal of Virological Methods 13 (1986) 245-253
		Van Der Poel, Cees L., "Hepatitis C virus: Into the fourth generation", VOX SANGUINIS, vol. 67, no. suppl. 3, 1994, pages 95-98
		Fonseca, et al., "Comparison of reactivity of sera tested in a third generation enzyme immunoassay (EIA) and recombinant immunoblot (RIBA) versus fourth generation EIA for antibody to hepatitis C virus (HCV)", 96h ASM General Meeting, 1996

23552 PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	